The lymphoproliferative disease of granular lymphocytes (LDGL), also r
eferred to as LGL leukemia, is a heterogeneous disorder, but is clinic
ally, morphologically, and immunologically distinct. Although LDGL has
recently been included in the revised classification of lymphomas as
an independent clinical entity, no consensus exists on the criteria to
establish the diagnosis. The aim of this report was to refine the par
ameters needed to make the diagnosis of LDGL. We studied II patients w
ith chronic granular lymphocytosis selected from among 195 cases obser
ved by our institutions from three different geographic areas (North A
merica, Europe, and Asia). These cases did not meet the current criter
ia for inclusion in LDGL, since all patients had less than 2,000 GL/mu
L. However, in each of these patients, we found evidence for expansio
n of a discrete GL population. Clonal rearrangement of the T-cell rece
ptor (TCR) beta gene was found in peripheral blood mononuclear cells (
PBMC) of all nine patients with CD3(+) LDGL. Using recently generated
monoclonal antibodies (MoAbs) against the TCR V beta gene regions, we
identified a unique TCR V beta on GL from each of three patients studi
ed. In two patients with CD3(-) LDGL, we also identified a restricted
pattern of reactivity, by staining with MoAbs against p58 antigen foun
d on normal natural killer (NK) cells. The clinical features of these
11 patients with relatively low absolute number of GL were similar to
those reported previously for patients with greater than 2,000 GL/mu L
. These data demonstrate that newer techniques such as MoAbs against V
beta gene regions and p58 molecules and molecular analyses are useful
to identify expansions of discrete GL proliferations. Demonstration o
f an expansion of a restricted GL subset is evidence for the diagnosis
of LDGL, even in patients with a relatively low GL count. Our results
also contribute to distinguish between the end of normality and the b
eginning of pathology in the broad spectrum of GL lymphocytoses. (C) 1
997 by The American Society of Hematology.